CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Chimeric antigen receptor T-cell therapy: Prospective observational study of unplanned emergency department presentations.
Chimeric antigen receptor T-cell therapy: Prospective observational study of unplanned emergency department presentations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
如果 CAR-T 疗法要更广泛地应用,尤其是在门诊诊疗模式下,就需要标准化的急诊科诊疗模式以识别特定的并发症。
CAR-T(CAR-T)细胞疗法是治疗难治性血液系统恶性肿瘤的新兴方法。CAR-T 治疗后患者计划外前往急诊科(ED),越来越突显了建立整合照护模式的必要性,以便及早识别 CAR-T 特异性并发症。
本研究为在三级医疗中心开展的前瞻性观察研究。治疗医师将全部 CAR-T 患者(n = 17)纳入研究登记,并由研究人员进行标记,使患者在 ED 分诊时触发 CAR-T 信息警示弹窗。研究人员回顾病历,评估 90 天内计划外就诊、并发症和患者结局。
CAR-T 患者常在治疗后 7 天内出现毒性,通常较轻,并发生于住院期间。病历审查发现 5 次计划外 ED 就诊,这些就诊被识别为 CAR-T 治疗后情况,但不能直接归因于特定毒性。
若 CAR-T 治疗将更广泛使用,尤其是在门诊照护模式下,就需要标准化急诊照护模式,以识别特定并发症。
Chimeric antigen receptor T-cell (CAR-T) therapy is an emerging treatment for refractory hematologic malignancy. Unplanned ED presentations following CAR-T present the increasing need for an integrated model of care that allows for the early recognition of its specific complications.
This is a prospective observational study at a tertiary centre. CAR-T patients (n = 17) were universally enrolled into a study registry by treating providers. These patients were flagged by investigators to trigger a pop-up notification CAR-T information warning at ED triage. Medical records were reviewed 90 days for unplanned presentations, complications and patient-oriented outcomes.
Patients receiving CAR-T frequently encountered toxicity within 7 days of therapy. This was typically mild and occurred in an inpatient setting. Medical record review revealed five unplanned ED presentations (that were recognised as post CAR-T) and not directly attributable to specific toxicities.
If CAR-T therapy is to be used more widely especially in an outpatient model of care, a standardised ED model of care for recognition of specific complications is needed.
MEMBER ACCOUNT
登录成功会直接打开下一页。